[Use of tenofovir monotherapy in a cohort of prisoners confined in the prisons of the Molise region and affected by mild HBV-related chronic hepatitis]
DOI:
https://doi.org/10.7175/cmi.v9i4.1218Keywords:
Tenofovir, HBV, Hepatitis B, HBV-DNA, HBsAgAbstract
Inmates are a population at risk for hepatitis B virus infection. It affects about 2% of Italian prisoners, while the prevalence in the Molise region seems to be higher, accounting for around 4% of the inmates.
The Authors report their experience in a penitentiary in the management of chronic hepatitis B with tenofovir. In particular, 10 male patients affected by HBV-related chronic hepatitis naïves to treatment confined in the prisons of the Molise region were treated with tenofovir 245 mg/die. The results show a satisfactory response, excellent tolerance, and no interruptions.
[Article in Italian]
References
Di Fiandra T, Voller F, Bazzerla G, et al. La salute dei detenuti in Italia: i risultati di uno studio multicentrico. Collana Documenti dell’Agenzia Regionale di Sanità della Toscana 2015; 83: 1-454. Disponibile all’indirizzo https://www.ars.toscana.it/it/pubblicazioni/collana-documenti-ars/pubblicazioni-2015/2977-la-salute-dei-detenuti-in-italia-i-risultati-di-uno-studio-multicentrico-2015.html (ultimo accesso dicembre 2015)
World Health Organization. Hepatitis B. Luglio 2015. Disponibile all’indirizzo http://www.who.int/mediacentre/factsheets/fs204/en/ (ultimo accesso dicembre 2015)
Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40; http://dx.doi.org/10.1186/1471-230X-7-40
Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302; http://dx.doi.org/10.1053/j.gastro.2012.02.017
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85; http://dx.doi.org/10.1016/j.jhep.2012.02.010
Brancaccio G, Giuberti T, Andreone P, et al. The evolving clinical profile of chronic HBV infection – the Italian master B cohort. Hepatology 2012/10/1 – AASLD 2012; 56: 639A-640A
Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIV–HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther 2010; 15: 963-74; http://dx.doi.org/10.3851/IMP1659; http://dx.doi.org/10.3851/IMP1649
Carosi G, Rizzetto M, Alberti A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011; 43: 259-65; http://dx.doi.org/10.1016/j.dld.2010.10.014
Bruno R, Caraceni P, Coco B, et al.; Associazione Italiana per lo Studio del Fegato (AISF). Libro bianco AISF 2011. Proposta per un piano nazionale per il controllo delle malattie epatiche. Disponibile all’indirizzo http://www.webaisf.org/media/13891/libro-bianco-aisf-2011.pdf (ultimo accesso dicembre 2015)
Stroffolini T, Spadaro A, Di Marco V, et al.; Gr.E.Ca.S. Hospitals’ Collaborating Group. Current practice of chronic hepatitis B treatment in Southern Italy. Eur J Intern Med 2012; 23: e124-e127; http://dx.doi.org/10.1016/j.ejim.2012.03.018
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2; http://dx.doi.org/10.1002/hep.23190
Marzano A, Angelucci E, Andreone P, et al.; Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408; http://dx.doi.org/10.1016/j.dld.2006.12.017
Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-7; http://dx.doi.org/10.1128/AAC.00138-06
Liaw YF, Leung N, Kao JH, et al.; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83; http://dx.doi.org/10.1007/s12072-008-9080-3
Centers for Disease Control and Prevention (CDC). Hepatitis B outbreak in a state correctional facility, 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 529-32
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)